Aimmune Therapeutics Inc. (AIMT) Sets New 1-Year Low at $10.46
Aimmune Therapeutics Inc. (NASDAQ:AIMT)’s share price hit a new 52-week low during mid-day trading on Tuesday . The stock traded as low as $10.46 and last traded at $10.50, with a volume of 128,200 shares trading hands. The stock had previously closed at $10.95.
Several equities analysts recently issued reports on AIMT shares. Piper Jaffray Cos. reissued an “overweight” rating and set a $38.00 price objective on shares of Aimmune Therapeutics in a report on Wednesday, June 29th. Wedbush reissued an “outperform” rating and set a $42.00 price objective on shares of Aimmune Therapeutics in a report on Monday, May 16th. Bank of America Corp. reissued a “buy” rating on shares of Aimmune Therapeutics in a report on Monday, May 16th. Finally, Zacks Investment Research raised shares of Aimmune Therapeutics from a “hold” rating to a “buy” rating and set a $16.00 price target on the stock in a report on Friday, May 20th. Five research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $33.40.
The stock’s market cap is $449.51 million. The stock has a 50-day moving average of $13.28 and a 200-day moving average of $14.75.
Aimmune Therapeutics (NASDAQ:AIMT) last issued its quarterly earnings data on Monday, May 16th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.40) by $0.03. On average, equities research analysts anticipate that Aimmune Therapeutics Inc. will post ($1.70) EPS for the current fiscal year.
In other news, major shareholder Foresite Capital Fund Ii, L.P. sold 240,000 shares of the company’s stock in a transaction that occurred on Tuesday, May 31st. The shares were sold at an average price of $15.23, for a total value of $3,655,200.00. The sale was disclosed in a document filed with the SEC, which is available through this link.
Other institutional investors recently modified their holdings of the company. Alps Advisors Inc. bought a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $1,027,000. Eagle Asset Management Inc. bought a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $15,794,000. TLP Group LLC bought a new position in shares of Aimmune Therapeutics during the fourth quarter valued at approximately $51,314,000. Finally, Aisling Capital LLC raised its position in shares of Aimmune Therapeutics by 6.0% in the fourth quarter. Aisling Capital LLC now owns 2,990,000 shares of the company’s stock valued at $55,166,000 after buying an additional 170,000 shares in the last quarter.
Aimmune Therapeutics Inc, formerly Allergen Research Corporation, is a United States-based clinical-stage biopharmaceutical company. The Company focuses on therapeutic approach, including the development of proprietary candidates, for the treatment of peanut and other food allergies. The Company’s Characterized Oral Desensitization Immunotherapy (CODIT) is a system designed to desensitize patients to food allergens using characterized biologic products, defined treatment protocols and support services.
Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.